Results 31 to 40 of about 8,177 (201)

Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections. [PDF]

J Med Virol
ABSTRACT This study aimed to assess the humoral immune response following administration of a BNT162b2 mRNA COVID‐19 booster dose and to evaluate its association with the development of SARS‐CoV‐2 infection after vaccination. Between July 2021 and February 2022, serum samples were collected from 313 individuals 28 days after receiving a COVID‐19 ...
Dinç HÖ, Uysal HK, Can G, Budak B, Daşdemir FO, Keskin E, Aydoğan O, Balkan İİ, Karaali R, Saribaş S, Ergin S, Saltoğlu N, Kocazeybek B.   +12 more
europepmc   +2 more sources

Value of anatomical partitioning of the retroperitoneal space in determining the origin of neurogenic tumors [PDF]

BMC Cancer
Background To analyze the anatomical partitioning of the retroperitoneal space and determine the distribution patterns of primary retroperitoneal neurogenic tumors (PRNTs).
Yuwei Li, Haowen Zhao, Jingjing Chen, Huacheng Chen, Guangmao Ni, Yanming Ge, Chunjing Liang, Peng Dong   +7 more
doaj   +2 more sources

A Modular Design of a Cholera Toxin B Subunit-Scaffolded Sub-Virion Nanoparticle Vaccine Against West Nile Virus. [PDF]

Microb Biotechnol
A recombinant West Nile virus (WNV) subunit vaccine was developed by displaying ED3 on a CTB scaffold. The fusion protein formed soluble nanoparticles in E. coli, eliciting strong, balanced, and specific neutralizing antibodies without cross‐reactivity, offering a safe, scalable subunit vaccine platform.
Byun H, Kim TH, Sung J, Lee JM, Shim SM, Kang SH, Kang H, Moon DH, Park SH, Kim D, Kim SJ, Kim S, Han G, Seong BL.   +13 more
europepmc   +2 more sources

An exploratory study to assess the influence of schistosomiasis on the occurrence of dengue virus in Madagascar [PDF]

Infectious Diseases of Poverty
Background Dengue virus (DENV) is the most prevalent mosquito-borne virus worldwide, with approximately half of the world’s population at risk of infection.
Jana Christina Hey, Tahinamandranto Rasamoelina, Anjarasoa Ravo Razafindrakoto, Nantenaina Matthieu Razafindralava, Zaraniaina Tahiry Rasolojaona, Stephanie Leyk, Sreejith Rajasekharan, Lucas Wilken, Tiana Randrianarisoa, Tojo Rémi Rafaralahivoavy, Jacques Hainasoa, Raphael Rakotozandrindrainy, Njary Randriamampionona, Norbert Georg Schwarz, Anna Jaeger, Aaron Remkes, Jean-Marc Kutz, Pia Rausche, Irina Kislaya, Valentina Marchese, Christa Ehmen, Christina Deschermeier, Jürgen May, Lidia Bosurgi, Rivo Andry Rakotoarivelo, Pietro Scaturro, Daniela Fusco   +26 more
doaj   +2 more sources

Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective

Nature Communications
The standard dengue virus (DENV) neutralization assay inconsistently predicts dengue protection. We compare how IgG ELISA, envelope domain III (EDIII), or non-structural protein 1 (NS1) binding antibodies, and titers from plaque reduction neutralization ...
Camila D. Odio, Jedas Veronica Daag, Maria Vinna Crisostomo, Charlie J. Voirin, Ana Coello Escoto, Cameron Adams, Lindsay Dahora Hein, Rosemary A. Aogo, Patrick I. Mpingabo, Guillermo Raimundi Rodriguez, Saba Firdous, Maria Abad Fernandez, Laura J. White, Kristal An Agrupis, Jacqueline Deen, Aravinda M. de Silva, Michelle Ylade, Leah C. Katzelnick   +17 more
doaj   +2 more sources

Chimeric Vesicular Stomatitis Virus Bearing Western Equine Encephalitis Virus Envelope Proteins E2-E1 Is a Suitable Surrogate for Western Equine Encephalitis Virus in a Plaque Reduction Neutralization Test [PDF]

Viruses
In December 2023, infections of western equine encephalitis virus (WEEV) within Argentina were reported to the World Health Organization (WHO). By April 2024, more than 250 human infections, 12 of which were fatal, and 2500 equine infections were ...
Kerri L. Miazgowicz, Bailey E. Maloney, Melinda A. Brindley, Mattie Cassaday, Raegan J. Petch, Paul Bates, Aaron C. Brault, Amanda E. Calvert   +7 more
doaj   +2 more sources

Considerations for changing PRNT Dengue 4 reference viruses: sub- optimal immunity to documented infections [PDF]

International Journal of Infectious Diseases, 2012
B. Thaisomboonsuk, R. Jarman, R. Gibbons, A. Nisalak, C. Klungthong, I. Yoon, Stephen J. Thomas, T. Endy, A. Rothman, T. Scott   +9 more
semanticscholar   +2 more sources

Montagem de controles internos para ensaios de PRNT: uma necessidade e um grande desafio [PDF]

Anais do VI Seminário Anual Científico e Tecnológico de Bio-Manguinhos, 2018
Felipe Figueiredo
exaly   +2 more sources

A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory

Viruses, 2022
A robust serological test to measure neutralizing antibodies against SARS-CoV-2 in biosafety level-2 (BSL-2) laboratories is useful for monitoring antibody response after vaccination or natural infection.
Jing Zou, Hongjie Xia, Pei-Yong Shi, Xuping Xie, Ping Ren   +4 more
doaj   +1 more source

Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

Frontiers in Cellular and Infection Microbiology, 2022
For the clinical application of semi-quantitative anti-SARS-CoV-2 antibody tests, the analytical performance and titer correlation of the plaque reduction neutralization test (PRNT) need to be investigated.
Beomki Lee, Jae-Hoon Ko, Jiho Park, Hee-Won Moon, Jin Yang Baek, Sunhee Jung, Hee-Young Lim, Kyung-Chang Kim, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Doo Ryeon Chung, Hee Jae Huh, Chi Ryang Chung, Yae-Jean Kim, Eun-Jeong Joo, Eun-Suk Kang, Kyong Ran Peck   +17 more
doaj   +1 more source